It could be demonstrated that this anti-S100A7 antibody, named 6F5, blocks S100A7/RAGE interaction, thereby inhibiting S100A7-mediated MMP9 activity, leading to decreased tumour growth, cell migration, and angiogenesis in a xenograft cancer model [235]. Here, MMP9 is linked to neoplasm.